BioCom is a leader in the emerging field of genomics - the discovery, analysis, and commercial development of genetic information. The Company believes the enormous information flowing from the human genome project will result in a paradigm shift in pharmaceutical drug development, and provide a new set of drug discovery tools. Genomic advances will allow identification of the molecular basis of common multi-factorial diseases such as cancer, mental illness, osteoporosis, asthma, and many others. In addition, genomics is leading to knowledge of the complete genetic structure of infectious pathogens. Genetic information will permit elucidation of the biochemical pathways responsible for the major diseases of mankind and will lead to novel therapeutic targets. In other words, the more that is seen, the more we realize what needs to be controlled and how to control it.

BioCom's approach to drug discovery represents a revolutionary change from traditional approaches. Historically, most drug discovery has been based on random screening of candidate drug compounds using assays that are believed to be associated with a disease state. Unfortunately, the link between a screening assay and the disease is seldom clear, as the genetic basis of most disease has not been elucidated. A molecular genetic approach allows scientists to first identify the genetic target causing a particular disease and then develop drugs to treat the root cause of the disease. BioCom expects to identify genes involved in important human diseases as well as all the genes of selected pathogenic organisms.

Any successful medical treatment begins with visualization and representation. Preventative medicine also requires proper visual intelligence. The better the vision, the more time available to configure a counterattack. The significant principle here is that vision equals control. From the macro to the micro (the Human Genome Project being the best known), no stone can remain unturned. Every aspect of the body must be open to the vision of medical and scientific authority. Once the body is thoroughly mapped and its "mechanistic" splendor revealed, any body invader (organic or otherwise) can be eliminated, and the future of that body can be accurately predicted.

Success in genomics requires powerful interdisciplinary skills in gene mapping, DNA sequencing and bioinformatics (computational molecular biology). Over the past decade, BioCom has built these core skills into a major genomics program. BioCom's program has been recognized and supported by the government-sponsored Human Genome Project, with billions in genome-based contracts and grants awarded to BioCom since 1991.

The mapped body is the quantified body. Its use is measured down to the penny. Without such a development, how could any consumer trust in the markets of the flesh machine?